Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

US stocks slid Thursday and the S&P 500 closed in correction, down more than 10% from its record high in February, as ...

It’s been a bad month for the stock market. But it’s been a terrible month—in fact, a terrible year—for Tesla. Even after ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price ...

Robert Morris—the televangelist who “spiritually advised” Trump during his 2016 campaign—has been indicted by a grand jury in Oklahoma on five felony counts of lewd or indecent acts with a 12-year-old ...

Various factors have weighed on tech stocks this year, including investor unease over Trump's tariffs and AI spending.